First Eagle Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

First Eagle Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-200	Closed	-$4K	–	281
2017 Q4	$4K	Hold	200	–	–	﹤0.01%	323
2017 Q3	$4K	Hold	200	–	–	﹤0.01%	341
2017 Q2	$7K	Hold	200	–	–	﹤0.01%	317
2017 Q1	$6K	Hold	200	–	–	﹤0.01%	310
2016 Q4	$7K	Hold	200	–	–	﹤0.01%	313
2016 Q3	$9K	Hold	200	–	–	﹤0.01%	330
2016 Q2	$10K	Sell	200 -1,915,460	-100%	-$102M	﹤0.01%	337
2016 Q1	$103M	Sell	1,915,660 -2,455,959	-56%	-$144M	0.26%	99
2015 Q4	$287M	Sell	4,371,619 -95,392	-2%	-$5.9M	0.72%	52
2015 Q3	$252M	Buy	4,467,011 +710,013	+19%	+$46M	0.64%	53
2015 Q2	$222M	Sell	3,756,998 -448,483	-11%	-$27.7M	0.53%	61
2015 Q1	$262M	Buy	4,205,481 +1,757,171	+72%	+$102M	0.62%	53
2014 Q4	$141M	Buy	2,448,310 +1,027,730	+72%	+$57.3M	0.34%	77
2014 Q3	$76.4M	Buy	1,420,580 +1,420,380	+710,190%	+$75.3M	0.19%	100
2014 Q2	$10K	Hold	200	–	–	﹤0.01%	318
2014 Q1	$11K	Hold	200	–	–	﹤0.01%	377
2013 Q4	$8K	Hold	200	–	–	﹤0.01%	363
2013 Q3	$8K	Hold	200	–	–	﹤0.01%	346
2013 Q2	$8K	Buy	+200	New	+$7.79K	﹤0.01%	342

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Eagle Investment Management's TEVA Position: Q1 2018 in Review

First Eagle Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 200 shares — an estimated $4K sold.

First Eagle Investment Management first reported a position in TEVA in Q2 2013 and held it in 19 quarters. The position peaked at $287M in Q4 2015. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

First Eagle Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
First Eagle Investment Management sold 200 Teva Pharmaceuticals shares in Q1 2018, an estimated $4K.
First Eagle Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 19 quarters.
First Eagle Investment Management's Teva Pharmaceuticals position peaked at $287M in Q4 2015.
506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on First Eagle Investment Management's 13F filing for Q1 2018, filed 4 May 2018.